Stocks and Investing Stocks and Investing
Thu, January 3, 2019
Wed, January 2, 2019

Amit Hazan Downgraded (ABT) to Strong Sell and Decreased Target to $68 on, Jan 2nd, 2019


Published on 2024-10-26 11:26:47 - WOPRAI, Amit Hazan
  Print publication without navigation


Amit Hazan of Citigroup, Downgraded "Abbott Laboratories" (ABT) to Strong Sell and Decreased Target from $72 to $68 on, Jan 2nd, 2019.

Amit has made no other calls on ABT in the last 4 months.



There are 6 other peers that have a rating on ABT. Out of the 6 peers that are also analyzing ABT, 0 agree with Amit's Rating of Hold.



These are the ratings of the 6 analyists that currently disagree with Amit


  • Matt Miksic of "Credit Suisse" Initiated at Buy and Held Target at $82 on, Tuesday, December 18th, 2018
  • Isaac Ro of "Goldman Sachs" Upgraded from Hold to Strong Buy and Increased Target to $81 on, Friday, November 30th, 2018
  • Jayson Bedford of "Raymond James" Maintained at Buy with Increased Target to $79 on, Thursday, October 18th, 2018
  • Matthew Taylor of "Barclays" Initiated at Buy and Held Target at $80 on, Tuesday, October 16th, 2018
  • Robbie Marcus of "JP Morgan" Maintained at Buy with Increased Target to $81 on, Monday, October 8th, 2018
  • Larry Biegelsen of "Wells Fargo" Maintained at Buy with Increased Target to $80 on, Monday, September 24th, 2018

Contributing Sources